---
title: 'Nedosiran Safety and Efficacy in PH1: Interim Analysis of PHYOX3'
date: '2024-05-06'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38707801/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240506181220&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSION: Nedosiran was well-tolerated in patients with PH1, and treatment
  resulted in a sustained, substantial reduction in Uox excretion for at least 30
  months in this long-term study. No safety signals have been identified to date.
  The PHYOX3 study is ...'
disable_comments: true
---
CONCLUSION: Nedosiran was well-tolerated in patients with PH1, and treatment resulted in a sustained, substantial reduction in Uox excretion for at least 30 months in this long-term study. No safety signals have been identified to date. The PHYOX3 study is ...